Article
Comparison Study of Dendritic Cell Vaccine with and without Cyclophosphamide to Treat Stage IV Melanoma Patients
This trial is evaluating whether the combination of chemotherapy (cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.
Study Type: Interventional
Age/Sex Requirement: 21-75 years (None)
Sponsor: Baylor Research Institute
ClinicalTrials.gov Identifier: NCT00722098
Purpose: To determine whether the combination of chemotherapy (cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.
Related Videos
Related Content
